Daiichi Sankyo aims for 180 bn yen op profit in FY2012

RELATED NEWS Daiichi Sankyo Q3 profit up, outlook lifted ALSO READ News and Notices about See interviews with Management See what other Experts & Brokerages are saying about See previous Results of

Daiichi Sankyo, Japan's third-largest drugmaker, said on Friday it is targeting an operating profit of 180 billion yen (USD 2 billion) on revenues of 1.15 trillion yen in the year to March 2013.
The firm also said it targets a return on equity of 10% or more and earnings per share of 140 yen or more in that financial year, against 5.2% and 63.9 yen estimated for the current year.
The company, which bought a majority stake in India's Ranbaxy Laboratories in 2008 to diversify its operations into generic drugs and emerging markets, said it expects overseas operations to account for 650 billion yen of the targeted overall revenue.
For the current year ending on March 31, the company has forecast an operating profit of 96 billion yen on revenues of 960 billion yen.
Analysts on average expect Daiichi Sankyo to generate an operating profit of 124.5 billion yen on revenues of 1.03 trillion yen in the year to March 2012, according to a poll by Thomson Reuters I/B/E/S.
Daiichi Sankyo president Takashi Shoda will give a briefing on the company's mid-term business plan later on Friday.